Palisade Capital Management LP Acquires Shares of 210,024 Bruker Corporation $BRKR

Key Points

• Palisade Capital Management acquired 210,024 Bruker shares worth approximately $12.6 million, while institutional investors collectively own 79.52% of the company.
• Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $56.64; recent targets range as high as $70.
• Bruker exceeded quarterly EPS expectations with $0.49 versus $0.38 expected, while revenue rose 5.2% year over year to $838.5 million. The company also declared a quarterly dividend of $0.05 per share.

Palisade Capital Management LP bought a new position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 210,024 shares of the medical research company's stock, valued at approximately $12,639,000. Palisade Capital Management LP owned 0.14% of Bruker as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in BRKR. Orbis Allan Gray Ltd boosted its position in shares of Bruker by 5.4% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company's stock worth $702,256,000 after purchasing an additional 761,258 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in Bruker in the second quarter valued at about $570,746,000. State Street Corp lifted its stake in Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company's stock valued at $180,700,000 after buying an additional 91,706 shares during the period. AQR Capital Management LLC lifted its stake in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after buying an additional 1,850,215 shares during the period. Finally, Sculptor Capital LP boosted its holdings in Bruker by 9.0% during the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock worth $118,112,000 after buying an additional 270,000 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Analysts Set New Price Targets

BRKR has been the subject of a number of recent analyst reports. Guggenheim upped their price target on Bruker from $50.00 to $70.00 and gave the company a "buy" rating in a research note on Monday, June 29th. TD Cowen reissued a "hold" rating on shares of Bruker in a research note on Wednesday, July 15th. JPMorgan Chase & Co. boosted their price objective on shares of Bruker from $55.00 to $65.00 and gave the company an "overweight" rating in a report on Monday, June 8th. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research note on Wednesday, August 5th. Finally, Wolfe Research assumed coverage on shares of Bruker in a report on Monday, June 1st. They issued a "peer perform" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Bruker presently has a consensus rating of "Moderate Buy" and an average price target of $56.64.

Bruker Trading Down 0.2%

NASDAQ:BRKR opened at $56.85 on Wednesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The business's 50-day simple moving average is $58.69 and its 200-day simple moving average is $47.71. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $65.30. The stock has a market capitalization of $8.66 billion, a PE ratio of -81.21, a price-to-earnings-growth ratio of 1.74 and a beta of 1.28.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to analysts' expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 21st. Bruker's dividend payout ratio is -28.57%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source